What PTAB Markush Rejection Means For Biotech Applicants

Law360, New York (March 16, 2017, 12:19 PM EDT) -- Jeff B. Vockrodt

Christopher H. Yaen The Patent Trial and Appeal Board for the first time in many years affirmed an examiner’s rejection of a claim as an “improper Markush” in Ex parte Chettier.[1] Patent examiners have increasingly turned to “Markush rejections”[2] in the wake of the U.S. patent and Trademark Office’s 2011 guidelines on the subject.[3] This controversial practice attempts to force patent applicants to narrow their claimed genus or other Markush-type group even when those claims meet all other conditions for patentability such as...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.